Remiges Ventures
News
2023.03.31Capacity Bio, For Which Remiges Ventures Was Founding Investor, Raised $35M
2023.01.04Remiges Portfolio Companies Raised In Aggregate More Than $145 million in 2022
2022.12.23Immunohelix Co., Ltd, one of our portfolio companies, was selected for AMED Strengthening Program for Pharmaceutical Venture Ecosystem
2022.09.26Remiges Ventures led the Series A round of finance for Kupando GmbH in Germany
2022.06.30Remiges selected as Certified VC by the AMED Strengthening Program for Pharmaceutical Venture Ecosystem
2022.06.06Luca Science, one of our portfolio companies in Japan, closed a $30.3M Series B round
2022.06.02Tranquis Therapeutics Announces Successful Completion of Phase 1 Clinical Trial of TQS-168
2022.03.08Digestome Therapeutics announced first patient enrolled in Phase 1 clinical trial of DGX-001
2022.02.04Remiges Ventures co-led the Series Seed round of finance for Restore Vision, Inc. in Japan
2022.01.10Inflects Bioscience receives approval from French regulatory authority to conduct a Phase 2 Clinical Trial for IFB-088 for ALS
2021.06.23Remiges joined Series B Round of Glycomine in California
2021.05.27The core technology of Imel BioTherapeutics, Inc. was published in Scientific Reports
2021.04.09Remiges Ventures Closes Second Fund with $95 million; Launches RDiscovery Incubator
2020.12.10Remiges led the Series A round of finance for Cyrano Therapeutics in Washington D.C.
2020.07.09Remiges co-led the Series A round of finance for Tranquis Therapeutics in California
2020.04.20Remiges led the Series A round of finance for Phost'In Therapeutics in France
2020.03.01Remiges Welcomes New Team Member
2020.01.07Inflectis BioScience announced successful completion of Phase 1 clinical trial of IFB-088
2020.01.01Remiges Welcomes New Team Member
2019.04.01Remiges created our third seed stage company based on intellectual properties from the Japanese academia
2019.04.01Remiges created our second seed stage company based on intellectual properties from the Japanese academia
2019.02.04ENB Therapeutics one of the Remiges Ventures' portfolio companies announced its clinical trial collaboration with Merck
2018.11.02OMEICOS Therapeutics one of the Remiges Ventures' portfolio companies closed its €17m Series C financing
2018.09.21Remiges led the Series A round of finance for ENB Therapeutics in New York
2018.06.27Remiges created a de novo company based on intellectual properties from a national university in Japan
2018.06.13Remiges joined Series A1 Round of KisoJi Biotechnology in Montreal Canada
2017.10.04Remiges joined Extension of Series B Round of Omeicos Therapeutics to expand its technology into Ophthalmology
2017.06.27Remiges led the Series A round of finance for Mitoconix Bio in Israel
2017.03.06Remiges Welcomes New Partner
2017.02.14The final closing of Remiges BioPharma Fund achieved raising a total $80 million
2016.06.01Remiges co-led the Series A round of finance for InFlectis BioScience in France
2016.04.19Remiges selected as Certified VC by the NEDO Technology-based Startup Support Program